Af302 News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Af302. Real-time updates on events, politics, business and more.

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA

July 7, 2022

Positive biomarker data confirmed in additional subjects and at additional timepoints Stable or continuously increasing cognitive, language and motor functions observed in patients treated

United States Raymond Wang Foundation Of Caring Multidisciplinary Lysosomal Disorder Program Sanfilippo Community Conference Weizmann Institute Of Science Bayley Scales Of Infant Development

Source: finanznachrichten.de

Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights

January 13, 2022

Lysogene remains focused on developing its pipeline led by LYS-SAF302, LYS-GM101, Fragile X and other high potential preclinical projects Regulatory News: Lysogene (FR0013233475 LYS) (Paris:LYS)

France General Karen Aiachadded Gaucher Parkinson Karen Aiach European Union Orphan Drug Designation

Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Af302 News Today

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA

Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights

Explore More Categories